Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finger-stick glucose testing as an institutional stressor: Staff perspectives from long-term care.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Pharmacological inhibition of perforin dampens CD8<sup>+</sup> T cell-mediated beta cell destruction in autoimmune diabetes in mice.

Diabetologia·2026
Same author

The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.

Medicina (Kaunas, Lithuania)·2026
Same author

Using Textural Analysis of Thermal Imaging to Predict Healing Status of Diabetes-Related Neuropathic Foot Ulcers: Protocol for a Co-Design and Longitudinal Study.

JMIR research protocols·2026
Same author

Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset.

Diabetes technology & therapeutics·2025
Same author

Omega-3 fatty acid supplementation for distal symmetrical peripheral neuropathy in adults with diabetes mellitus.

The Cochrane database of systematic reviews·2025

Related Experiment Video

Updated: Jul 7, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

Eye Health Among Islet Cell Transplant Recipients With Long-duration Type 1 Diabetes.

Hye Jin Kwon1,2, Sybil A McAuley1,2,3,4, Richard J MacIsaac1,2,5

  • 1Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.

Transplantation Direct
|July 6, 2026
PubMed
Summary
This summary is machine-generated.

Islet cell transplantation (ICT) may stabilize eye health in type 1 diabetes (T1D) patients with long-standing disease. Further research is needed to monitor eye health outcomes post-transplantation.

More Related Videos

Transplantation into the Anterior Chamber of the Eye for Longitudinal, Non-invasive In vivo Imaging with Single-cell Resolution in Real-time
05:54

Transplantation into the Anterior Chamber of the Eye for Longitudinal, Non-invasive In vivo Imaging with Single-cell Resolution in Real-time

Published on: March 10, 2013

A Method for Islet Transplantation to the Omentum in Mouse
06:25

A Method for Islet Transplantation to the Omentum in Mouse

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

Transplantation into the Anterior Chamber of the Eye for Longitudinal, Non-invasive In vivo Imaging with Single-cell Resolution in Real-time
05:54

Transplantation into the Anterior Chamber of the Eye for Longitudinal, Non-invasive In vivo Imaging with Single-cell Resolution in Real-time

Published on: March 10, 2013

A Method for Islet Transplantation to the Omentum in Mouse
06:25

A Method for Islet Transplantation to the Omentum in Mouse

Published on: January 7, 2019

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Transplantation Medicine

Background:

  • Diabetic retinopathy (DR) is a leading cause of blindness in type 1 diabetes (T1D).
  • Islet cell transplantation (ICT) is an option for T1D patients with severe hypoglycemia.
  • Rapid glycemic control post-ICT may affect DR progression.

Purpose of the Study:

  • To explore eye health outcomes in adult T1D patients following ICT.
  • To assess changes in diabetic retinopathy and other retinal pathologies post-ICT.

Main Methods:

  • Retrospective study of ICT recipients at a tertiary institution (2007-2022).
  • Included patients with successful ICT and available pre/post-transplant eye data.
  • Assessed eye health outcomes relative to ICT.

Main Results:

  • Sixteen T1D patients (30 eyes) were followed for 5 years.
  • Hemoglobin A1c improved significantly post-ICT (-1.2%).
  • 56% had DR pre-ICT; 25% showed worsening eye outcomes post-ICT, with no new proliferative DR cases. Four experienced "early worsening" not linked to DR progression. Worsening outcomes correlated with higher HbA1c and lower C-peptide.

Conclusions:

  • ICT may stabilize eye health in select T1D patients with long-duration disease.
  • Systematic, long-term eye health monitoring is crucial for ICT recipients.